ADMA Biologics, Inc. (ADMA)

6,55 +0,11 (+1,71%) Alla chiusura: 04:00PM EDT

ADMA Biologics, Inc.

465 State Route 17
Ramsey, NJ 07446
United States
201 478 5552
https://www.admabiologics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 624

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Adam S. Grossman	Co-Founder, President, CEO, Interim CFO & Director	1,59M	N/D	1977
Dr. Jerrold B. Grossman D.P.S., Ph.D.	Co-Founder & Vice Chairman of the Board	90k	N/D	1948
Ms. Kaitlin Kestenberg	COO & Senior VP of Compliance	N/D	N/D	1987
Mr. Drew Pantello	Vice President of Marketing & Corporate Development	N/D	N/D	N/D
Ms. Cindy Petersen	Executive Director of Human Resources	N/D	N/D	N/D
Mr. Skyler Bloom	Senior Director of Business Development & Corporate Strategy	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di ADMA Biologics, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.